Aspirin Exacerbated Respiratory Disease Market Trends

Growth Drivers

• Increased government spending via Medicare and Medicaid: Medicare Part D spending on asthma-related biologics in the U.S., such as Dupilumab (Dupixent) and Mepolizumab (Nucala), reached USD 4.9 billion in 2023. Dupixent reached nearly USD 1.7 billion for chronic respiratory inflammation, impacting the federal investment in targeted therapies. This has highlighted the rising adoption of biologics and aligns with Medicare for cost-effective, high-need patient groups via reimbursable specialty pharmaceuticals. Further, the expansion of reimbursement under Medicare improves patient access and stimulates the growth of the aspirin exacerbated respiratory disease market.
• Healthcare quality improvement and cost reduction initiatives: According to the AHRQ report in 2022, the initiation of biologic treatment in the initial phases of aspirin-exacerbated respiratory disease asthma phenotypes experienced a 35.4% decrease in emergency hospitalizations. This directs cost savings of USD 460.4 million over two years. These results are consistent with the integration of biologics into evidence-based treatment guidelines for the management of asthma and sinusitis. Further, the AHRQ suggested that such interventions for general healthcare quality improvement emphasize their ability to reduce hospital dependence and lower total system costs. These findings have shaped payer payment policies and facilitated value-based care implementation.

Challenges

High treatment costs and patient affordability: The cost of biologics related to aspirin exacerbated respiratory disease, such as dupilumab, reached USD 40,002 per patient annually in the U.S., making a burden for private and public healthcare systems. As per the CDC report, nearly 38.3% of asthma patients are eligible under Medicare and received access to biologics therapies in 2023, mainly due to restrictive cost-based eligibility. These access issues limit the adoption of aspirin-exacerbated respiratory disease treatment mainly in underserved populations. Further, manufacturers are experiencing the pressure of cost-effectiveness to offset out-of-pocket costs.